Please try another search
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
David S. Grayzel | 54 | 2020 | Independent Director |
Timothy P. Noyes | 61 | 2021 | CEO & Director |
Christian S. Schade | 62 | 2023 | Independent Director |
Joshua Resnick | 50 | 2020 | Independent Director |
Donald J. Santel | 63 | 2023 | Independent Director |
Habib Joseph Dable | 55 | 2023 | Independent Chairman of the Board |
Maha Mehdi Katabi | 51 | 2020 | Independent Director |
Mark T. Iwicki | 58 | 2021 | Independent Director |
Allison Dorval | 48 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review